Science and Research

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults

To estimate the efficacy of AZD7442 in the prevention of the composite endpoint of either severe COVID-19 or death from any cause through
study Day 29

Study details
Study-ID: 2020-005315-44
Study-ID: 2020-005315-44
DZL Disease Area: PALI
DZL Disease Area: PALI
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: BREATH
DZL Participating Sites: BREATH
Start Date: 26.02.2021
Completion Date: 10.03.2023
Status: Closed
Status: Closed
DZL recruiting center


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.